Harewood, R.* ; Rothwell, J.A.* ; Bešević, J.* ; Viallon, V.* ; Achaintre, D.* ; Gicquiau, A.* ; Rinaldi, S.* ; Wedekind, R.* ; Prehn, C. ; Adamski, J. ; Schmidt, J.A.* ; Jacobs, I.* ; Tjønneland, A.* ; Olsen, A.* ; Severi, G.* ; Kaaks, R.* ; Katzke, V.* ; Schulze, M.B.* ; Prada, M.* ; Masala, G.* ; Agnoli, C.* ; Panico, S.* ; Sacerdote, C.* ; Jakszyn, P.* ; Sánchez, M.J.* ; Castilla, J.* ; Chirlaque, M.D.* ; Atxega, A.A.* ; van Guelpen, B.* ; Heath, A.K.* ; Papier, K.* ; Tong, T.Y.N.* ; Summers, S.A.* ; Playdon, M.C.* ; Cross, A.J.* ; Keski-Rahkonen, P.* ; Chajès, V.* ; Murphy, N.* ; Gunter, M.J.*
Association between pre-diagnostic circulating lipid metabolites and colorectal cancer risk: A nested case-control study in the European Prospective Investigation into Cancer and Nutrition (EPIC).
EBioMedicine 101:105024 (2024)
BACKGROUND: Altered lipid metabolism is a hallmark of cancer development. However, the role of specific lipid metabolites in colorectal cancer development is uncertain. METHODS: In a case-control study nested within the European Prospective Investigation into Cancer and Nutrition (EPIC), we examined associations between pre-diagnostic circulating concentrations of 97 lipid metabolites (acylcarnitines, glycerophospholipids and sphingolipids) and colorectal cancer risk. Circulating lipids were measured using targeted mass spectrometry in 1591 incident colorectal cancer cases (55% women) and 1591 matched controls. Multivariable conditional logistic regression was used to estimate odds ratios (ORs) and 95% confidence intervals (CIs) for associations between concentrations of individual lipid metabolites and metabolite patterns with colorectal cancer risk. FINDINGS: Of the 97 assayed lipids, 24 were inversely associated (nominally p < 0.05) with colorectal cancer risk. Hydroxysphingomyelin (SM (OH)) C22:2 (ORper doubling 0.60, 95% CI 0.47-0.77) and acylakyl-phosphatidylcholine (PC ae) C34:3 (ORper doubling 0.71, 95% CI 0.59-0.87) remained associated after multiple comparisons correction. These associations were unaltered after excluding the first 5 years of follow-up after blood collection and were consistent according to sex, age at diagnosis, BMI, and colorectal subsite. Two lipid patterns, one including 26 phosphatidylcholines and all sphingolipids, and another 30 phosphatidylcholines, were weakly inversely associated with colorectal cancer. INTERPRETATION: Elevated pre-diagnostic circulating levels of SM (OH) C22:2 and PC ae C34:3 and lipid patterns including phosphatidylcholines and sphingolipids were associated with lower colorectal cancer risk. This study may provide insight into potential links between specific lipids and colorectal cancer development. Additional prospective studies are needed to validate the observed associations. FUNDING: World Cancer Research Fund (reference: 2013/1002); European Commission (FP7: BBMRI-LPC; reference: 313010).
Impact Factor
Scopus SNIP
Web of Science
Times Cited
Scopus
Cited By
Altmetric
Publikationstyp
Artikel: Journalartikel
Dokumenttyp
Wissenschaftlicher Artikel
Typ der Hochschulschrift
Herausgeber
Schlagwörter
Acylcarnitines ; Colorectal Cancer ; Glycerophospholipids ; Lipids ; Metabolomics ; Sphingolipids; C-reactive Protein; Treelet Transform; Fatty-acids; Serum; Colon; Metaanalysis; Patterns; Database; Choline; Markers
Keywords plus
Sprache
englisch
Veröffentlichungsjahr
2024
Prepublished im Jahr
0
HGF-Berichtsjahr
2024
ISSN (print) / ISBN
2352-3964
e-ISSN
2352-3964
ISBN
Bandtitel
Konferenztitel
Konferzenzdatum
Konferenzort
Konferenzband
Quellenangaben
Band: 101,
Heft: ,
Seiten: ,
Artikelnummer: 105024
Supplement: ,
Reihe
Verlag
Elsevier
Verlagsort
Amsterdam [u.a.]
Tag d. mündl. Prüfung
0000-00-00
Betreuer
Gutachter
Prüfer
Topic
Hochschule
Hochschulort
Fakultät
Veröffentlichungsdatum
0000-00-00
Anmeldedatum
0000-00-00
Anmelder/Inhaber
weitere Inhaber
Anmeldeland
Priorität
Begutachtungsstatus
Peer reviewed
POF Topic(s)
30505 - New Technologies for Biomedical Discoveries
30201 - Metabolic Health
Forschungsfeld(er)
Enabling and Novel Technologies
Genetics and Epidemiology
PSP-Element(e)
A-630710-001
G-500600-001
Förderungen
European Commission
World Cancer Research Fund
Copyright
Erfassungsdatum
2024-04-30